The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Biogeneric Drugs-Global Market Insights and Sales Trends 2024
Synopsis
Biogenerics drugs are the biological products manufactured after end of patent of innovator biopharmaceuticals. Biogenerics also known as biosimilars in Europe, follows-on-biologics in US and subsequent entry biological in japan. Due to their high degree of similarity with the biological reference product, they have no clinically evidenced and meaningful differences from the reference product in terms of quality, safety or efficacy. Biogenerics drugs provide effective treatment for number of serious and life-threatening illness because of their high specificity and activity. Biogeneric are more complex compared to small molecule drugs. Their quality and safety are highly dependent on the process of production (choice of cell type, development of the genetically modified cell for production, etc.), purification and formulation. The constitution of the biogeneric drugs can be either small molecules such as human insulin or erythropoietin, or complex molecules such as monoclonal antibodies. Biogeneric drugs are increasing gaining prominence given the loss of exclusivity of big branded drugs. In Europe, biogenerics can be marketed through independent applicant following expiry of patent and market exclusivity periods of the reference product. Regulatory harmonization, naming and labelling, innovative licensure norms and route to market for the biogeneric drugs are issues expected to gain attention and traction from big drug makers in the forthcoming years.
The global Biogeneric Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Biogeneric Drugs in various end use industries. The expanding demands from the Hospital, Clinics and Research Centers,, are propelling Biogeneric Drugs market. Insulins, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Growth Hormones segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Biogeneric Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Biogeneric Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Biogeneric Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Biogeneric Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Biogeneric Drugs covered in this report include Sandoz International, Teva pharmaceutical industries, Mylan, 3SBio, Shanghai Fosun Pharmaceutical, Tonghua Dongbao Pharmaceutical, Biocon, Reliance life sciences and Probiomed, etc.
The global Biogeneric Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Sandoz International
Teva pharmaceutical industries
Mylan
3SBio
Shanghai Fosun Pharmaceutical
Tonghua Dongbao Pharmaceutical
Biocon
Reliance life sciences
Probiomed
Biosidus
AMEGA Biotech
Celltrion
LG life Science
Dong-A Pharmaceutical
Global Biogeneric Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Biogeneric Drugs market, Segment by Type:
Insulins
Growth Hormones
Monoclonal Antibodies
Others
Global Biogeneric Drugs market, by Application
Hospital
Clinics
Research Centers
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Biogeneric Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Biogeneric Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Biogenerics drugs are the biological products manufactured after end of patent of innovator biopharmaceuticals. Biogenerics also known as biosimilars in Europe, follows-on-biologics in US and subsequent entry biological in japan. Due to their high degree of similarity with the biological reference product, they have no clinically evidenced and meaningful differences from the reference product in terms of quality, safety or efficacy. Biogenerics drugs provide effective treatment for number of serious and life-threatening illness because of their high specificity and activity. Biogeneric are more complex compared to small molecule drugs. Their quality and safety are highly dependent on the process of production (choice of cell type, development of the genetically modified cell for production, etc.), purification and formulation. The constitution of the biogeneric drugs can be either small molecules such as human insulin or erythropoietin, or complex molecules such as monoclonal antibodies. Biogeneric drugs are increasing gaining prominence given the loss of exclusivity of big branded drugs. In Europe, biogenerics can be marketed through independent applicant following expiry of patent and market exclusivity periods of the reference product. Regulatory harmonization, naming and labelling, innovative licensure norms and route to market for the biogeneric drugs are issues expected to gain attention and traction from big drug makers in the forthcoming years.
The global Biogeneric Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Biogeneric Drugs in various end use industries. The expanding demands from the Hospital, Clinics and Research Centers,, are propelling Biogeneric Drugs market. Insulins, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Growth Hormones segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Biogeneric Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Biogeneric Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Biogeneric Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Biogeneric Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Biogeneric Drugs covered in this report include Sandoz International, Teva pharmaceutical industries, Mylan, 3SBio, Shanghai Fosun Pharmaceutical, Tonghua Dongbao Pharmaceutical, Biocon, Reliance life sciences and Probiomed, etc.
The global Biogeneric Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Sandoz International
Teva pharmaceutical industries
Mylan
3SBio
Shanghai Fosun Pharmaceutical
Tonghua Dongbao Pharmaceutical
Biocon
Reliance life sciences
Probiomed
Biosidus
AMEGA Biotech
Celltrion
LG life Science
Dong-A Pharmaceutical
Global Biogeneric Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Biogeneric Drugs market, Segment by Type:
Insulins
Growth Hormones
Monoclonal Antibodies
Others
Global Biogeneric Drugs market, by Application
Hospital
Clinics
Research Centers
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Biogeneric Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Biogeneric Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Biogeneric Drugs Market Overview
1.1 Biogeneric Drugs Product Overview
1.2 Biogeneric Drugs Market Segment by Type
1.2.1 Insulins
1.2.2 Growth Hormones
1.2.3 Monoclonal Antibodies
1.2.4 Others
1.3 Global Biogeneric Drugs Market Size by Type
1.3.1 Global Biogeneric Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global Biogeneric Drugs Historic Market Size Review by Type (2018-2023)
1.3.3 Global Biogeneric Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Biogeneric Drugs Sales Breakdown by Type (2018-2023)
1.4.2 Europe Biogeneric Drugs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Biogeneric Drugs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Biogeneric Drugs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Biogeneric Drugs Sales Breakdown by Type (2018-2023)
2 Global Biogeneric Drugs Market Competition by Company
2.1 Global Top Players by Biogeneric Drugs Sales (2018-2023)
2.2 Global Top Players by Biogeneric Drugs Revenue (2018-2023)
2.3 Global Top Players by Biogeneric Drugs Price (2018-2023)
2.4 Global Top Manufacturers Biogeneric Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Biogeneric Drugs Market Competitive Situation and Trends
2.5.1 Biogeneric Drugs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Biogeneric Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Biogeneric Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Biogeneric Drugs Market
2.8 Key Manufacturers Biogeneric Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Biogeneric Drugs Status and Outlook by Region
3.1 Global Biogeneric Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Biogeneric Drugs Historic Market Size by Region
3.2.1 Global Biogeneric Drugs Sales in Volume by Region (2018-2023)
3.2.2 Global Biogeneric Drugs Sales in Value by Region (2018-2023)
3.2.3 Global Biogeneric Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Biogeneric Drugs Forecasted Market Size by Region
3.3.1 Global Biogeneric Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global Biogeneric Drugs Sales in Value by Region (2024-2029)
3.3.3 Global Biogeneric Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Biogeneric Drugs by Application
4.1 Biogeneric Drugs Market Segment by Application
4.1.1 Hospital
4.1.2 Clinics
4.1.3 Research Centers
4.2 Global Biogeneric Drugs Market Size by Application
4.2.1 Global Biogeneric Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global Biogeneric Drugs Historic Market Size Review by Application (2018-2023)
4.2.3 Global Biogeneric Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Biogeneric Drugs Sales Breakdown by Application (2018-2023)
4.3.2 Europe Biogeneric Drugs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Biogeneric Drugs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Biogeneric Drugs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Biogeneric Drugs Sales Breakdown by Application (2018-2023)
5 North America Biogeneric Drugs by Country
5.1 North America Biogeneric Drugs Historic Market Size by Country
5.1.1 North America Biogeneric Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Biogeneric Drugs Sales in Volume by Country (2018-2023)
5.1.3 North America Biogeneric Drugs Sales in Value by Country (2018-2023)
5.2 North America Biogeneric Drugs Forecasted Market Size by Country
5.2.1 North America Biogeneric Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America Biogeneric Drugs Sales in Value by Country (2024-2029)
6 Europe Biogeneric Drugs by Country
6.1 Europe Biogeneric Drugs Historic Market Size by Country
6.1.1 Europe Biogeneric Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Biogeneric Drugs Sales in Volume by Country (2018-2023)
6.1.3 Europe Biogeneric Drugs Sales in Value by Country (2018-2023)
6.2 Europe Biogeneric Drugs Forecasted Market Size by Country
6.2.1 Europe Biogeneric Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe Biogeneric Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific Biogeneric Drugs by Region
7.1 Asia-Pacific Biogeneric Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Biogeneric Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Biogeneric Drugs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Biogeneric Drugs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Biogeneric Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Biogeneric Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Biogeneric Drugs Sales in Value by Region (2024-2029)
8 Latin America Biogeneric Drugs by Country
8.1 Latin America Biogeneric Drugs Historic Market Size by Country
8.1.1 Latin America Biogeneric Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Biogeneric Drugs Sales in Volume by Country (2018-2023)
8.1.3 Latin America Biogeneric Drugs Sales in Value by Country (2018-2023)
8.2 Latin America Biogeneric Drugs Forecasted Market Size by Country
8.2.1 Latin America Biogeneric Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Biogeneric Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa Biogeneric Drugs by Country
9.1 Middle East and Africa Biogeneric Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Biogeneric Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Biogeneric Drugs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Biogeneric Drugs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Biogeneric Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Biogeneric Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Biogeneric Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Sandoz International
10.1.1 Sandoz International Company Information
10.1.2 Sandoz International Introduction and Business Overview
10.1.3 Sandoz International Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Sandoz International Biogeneric Drugs Products Offered
10.1.5 Sandoz International Recent Development
10.2 Teva pharmaceutical industries
10.2.1 Teva pharmaceutical industries Company Information
10.2.2 Teva pharmaceutical industries Introduction and Business Overview
10.2.3 Teva pharmaceutical industries Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Teva pharmaceutical industries Biogeneric Drugs Products Offered
10.2.5 Teva pharmaceutical industries Recent Development
10.3 Mylan
10.3.1 Mylan Company Information
10.3.2 Mylan Introduction and Business Overview
10.3.3 Mylan Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Mylan Biogeneric Drugs Products Offered
10.3.5 Mylan Recent Development
10.4 3SBio
10.4.1 3SBio Company Information
10.4.2 3SBio Introduction and Business Overview
10.4.3 3SBio Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 3SBio Biogeneric Drugs Products Offered
10.4.5 3SBio Recent Development
10.5 Shanghai Fosun Pharmaceutical
10.5.1 Shanghai Fosun Pharmaceutical Company Information
10.5.2 Shanghai Fosun Pharmaceutical Introduction and Business Overview
10.5.3 Shanghai Fosun Pharmaceutical Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Shanghai Fosun Pharmaceutical Biogeneric Drugs Products Offered
10.5.5 Shanghai Fosun Pharmaceutical Recent Development
10.6 Tonghua Dongbao Pharmaceutical
10.6.1 Tonghua Dongbao Pharmaceutical Company Information
10.6.2 Tonghua Dongbao Pharmaceutical Introduction and Business Overview
10.6.3 Tonghua Dongbao Pharmaceutical Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Tonghua Dongbao Pharmaceutical Biogeneric Drugs Products Offered
10.6.5 Tonghua Dongbao Pharmaceutical Recent Development
10.7 Biocon
10.7.1 Biocon Company Information
10.7.2 Biocon Introduction and Business Overview
10.7.3 Biocon Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Biocon Biogeneric Drugs Products Offered
10.7.5 Biocon Recent Development
10.8 Reliance life sciences
10.8.1 Reliance life sciences Company Information
10.8.2 Reliance life sciences Introduction and Business Overview
10.8.3 Reliance life sciences Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Reliance life sciences Biogeneric Drugs Products Offered
10.8.5 Reliance life sciences Recent Development
10.9 Probiomed
10.9.1 Probiomed Company Information
10.9.2 Probiomed Introduction and Business Overview
10.9.3 Probiomed Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Probiomed Biogeneric Drugs Products Offered
10.9.5 Probiomed Recent Development
10.10 Biosidus
10.10.1 Biosidus Company Information
10.10.2 Biosidus Introduction and Business Overview
10.10.3 Biosidus Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Biosidus Biogeneric Drugs Products Offered
10.10.5 Biosidus Recent Development
10.11 AMEGA Biotech
10.11.1 AMEGA Biotech Company Information
10.11.2 AMEGA Biotech Introduction and Business Overview
10.11.3 AMEGA Biotech Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
10.11.4 AMEGA Biotech Biogeneric Drugs Products Offered
10.11.5 AMEGA Biotech Recent Development
10.12 Celltrion
10.12.1 Celltrion Company Information
10.12.2 Celltrion Introduction and Business Overview
10.12.3 Celltrion Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
10.12.4 Celltrion Biogeneric Drugs Products Offered
10.12.5 Celltrion Recent Development
10.13 LG life Science
10.13.1 LG life Science Company Information
10.13.2 LG life Science Introduction and Business Overview
10.13.3 LG life Science Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
10.13.4 LG life Science Biogeneric Drugs Products Offered
10.13.5 LG life Science Recent Development
10.14 Dong-A Pharmaceutical
10.14.1 Dong-A Pharmaceutical Company Information
10.14.2 Dong-A Pharmaceutical Introduction and Business Overview
10.14.3 Dong-A Pharmaceutical Biogeneric Drugs Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Dong-A Pharmaceutical Biogeneric Drugs Products Offered
10.14.5 Dong-A Pharmaceutical Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Biogeneric Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Biogeneric Drugs Industrial Chain Analysis
11.4 Biogeneric Drugs Market Dynamics
11.4.1 Biogeneric Drugs Industry Trends
11.4.2 Biogeneric Drugs Market Drivers
11.4.3 Biogeneric Drugs Market Challenges
11.4.4 Biogeneric Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Biogeneric Drugs Distributors
12.3 Biogeneric Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
